Log In
Print
BCIQ
Print
Print this Print this
 

BT2111

  Manage Alerts
Collapse Summary General Information
Company biOasis Technologies Inc.
DescriptionTrastuzumab conjugated to the Transcend p97 carrier protein
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat brain metastasis in patients with HER2+ breast cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today